Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 11/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 4/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | LTK | P29376 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16236390 | 0.87 | ADK (0.54) | ADKSLC29A1MTORRAB9ASRC | |
| SCHEMBL29484542 | 0.87 | ADK (0.54) | ADKSLC29A1MTORRAB9ASRC | |
| SCHEMBL30373019 | 0.85 | ADK (0.45) | ADKSLC29A1MTORRAB9ASRC | |
| SCHEMBL1939761 | 0.85 | ADK (0.52) | ADKSLC29A1MTORRAB9ASRC | |
| SCHEMBL401328 | 0.85 | ADK (0.52) | ADKSLC29A1MTORRAB9ASRC | |
| SCHEMBL17749181 | 0.84 | ADK (0.54) | ADKMTORRAB9ASRCLCK | |
| SCHEMBL1443178 | 0.84 | ADK (0.47) | ADKSLC29A1MTORRAB9ASRC | |
| SCHEMBL16236685 | 0.83 | ADK (0.51) | ADKSLC29A1MTORRAB9ASRC | |
| SCHEMBL22086530 | 0.83 | ADK (0.51) | ADKSLC29A1MTORRAB9ASRC | |
| SCHEMBL30373169 | 0.83 | ADK (0.51) | ADKSLC29A1MTORRAB9ASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108631-B | 6-amino-7-bicyclic-7-deaza-purine derivatives as protein kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-03-05 | — | — | US | disclosed |
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-03-05 | — | — | US | disclosed |
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEICAL SCIENCES S.r.l. (IT) | 2017-11-16 | — | — | US | disclosed |
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEICAL SCIENCES S.r.l. (IT) | 2017-11-16 | — | — | US | disclosed |
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEICAL SCIENCES S.r.l. (IT) | 2017-11-16 | — | — | US | disclosed |
| EP-3218378-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016075224-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016075224-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, RET, ADK | ADK 3/4885SLC29A1 773/4885MTOR 274/4885 |
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | DCK, RET, PRKCA | ADK 4/4885SLC29A1 596/4885MTOR 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.